原发部位手术切除是否与就诊时即有转移的原发性恶性骨肿瘤患者总生存改善相关
基于美国国家癌症数据库2004至2016年2288例就诊时即有转移的原发性恶性骨肿瘤患者,46%接受原发部位手术切除。多因素Cox回归显示,原发部位手术切除与总死亡风险降低相关(HR 0.42,95%CI 0.36至0.49,p<0.001)。分层分析中,放疗与尤因肉瘤总生存改善相关,化疗与骨肉瘤和软骨肉瘤总生存改善相关。
要点
- 原发部位手术切除与转移性原发恶性骨肿瘤患者总死亡风险降低相关(HR 0.42)。
- 放疗与尤因肉瘤总生存改善相关(HR 0.71),骨肉瘤和软骨肉瘤未见此关联。
- 化疗与骨肉瘤(HR 0.50)和软骨肉瘤(HR 0.62)总生存改善相关,尤因肉瘤未见此关联。
核心结论
- 原发部位手术切除与就诊时即有转移的原发性恶性骨肿瘤患者的总生存获益相关。
- 作者认为需要利用更详细的转移灶数据(如大小、位置、数量和治疗)、化疗方案和放疗部位(原发或转移部位)开展进一步研究,以更好地理解哪些患者能从切除原发恶性肿瘤中获得总生存改善和/或生活质量获益。
研究设计与样本
- 查询2004至2016年美国国家癌症数据库(NCDB),使用国际疾病分类第3版拓扑编码识别四肢和/或骨盆原发性恶性骨肿瘤患者。
- 排除头或颅骨、躯干和脊柱的恶性骨肿瘤患者,排除美国癌症联合委员会指南分期为1、2或3期的患者,仅纳入就诊时即有转移的患者。
- 共纳入2288例原发性恶性骨肿瘤伴就诊时转移的患者(1121例骨肉瘤、345例软骨肉瘤、822例尤因肉瘤),其中46%(1053/2288)接受原发部位手术切除。
- 接受原发部位手术切除的患者中33%(348/1053)还接受了转移灶额外切除。
- 采用多因素Cox回归分析评估原发肿瘤手术切除与总生存的关联,控制基线人口学、肿瘤特征(分级、位置、组织学类型和肿瘤大小)和治疗模式(远处或区域转移灶切除、手术切缘阳性或阴性、放疗或化疗使用)的差异,并按组织学类型进行分层敏感性分析。
主要发现
- 控制基线人口学、肿瘤特征和治疗模式差异后,原发部位手术切除与未行原发部位切除者相比总死亡风险降低相关(HR 0.42,95%CI 0.36至0.49,p<0.001)。
- 分层分析中,放疗与尤因肉瘤患者总生存改善相关(HR 0.71,95%CI 0.57至0.88,p=0.002),但与骨肉瘤(HR 1.14,95%CI 0.91至1.43,p=0.643)或软骨肉瘤(HR 1.0,95%CI 0.78至1.50,p=0.643)总生存无显著关联。
- 化疗与骨肉瘤(HR 0.50,95%CI 0.39至0.64,p<0.001)和软骨肉瘤(HR 0.62,95%CI 0.45至0.85,p=0.003)总生存改善相关,但与尤因肉瘤总生存无显著关联(HR 0.7,95%CI 0.46至1.35,p=0.385)。
关键数值与推荐
- 原发部位手术切除与总死亡风险降低相关:HR 0.42(95%CI 0.36至0.49),p<0.001。
- 尤因肉瘤中放疗与总生存改善相关:HR 0.71(95%CI 0.57至0.88),p=0.002。
- 骨肉瘤中化疗与总生存改善相关:HR 0.50(95%CI 0.39至0.64),p<0.001。
- 软骨肉瘤中化疗与总生存改善相关:HR 0.62(95%CI 0.45至0.85),p=0.003。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要利用更详细的转移灶数据(如大小、位置、数量和治疗)、化疗方案和放疗部位(原发或转移部位)开展进一步研究,以更好地理解哪些患者能从切除原发恶性肿瘤中获得总生存改善和/或生活质量获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of primary malignant bone tumors in patients with metastatic disease at presentation remains a challenge. Although surgical resection has been a mainstay in the management of nonmetastatic malignant bone tumors, there is a lack of large-scale evidence-based guidance on whether surgery of the primary site/tumor improves overall survival in malignant bone tumors with metastatic disease at presentation. QUESTIONS/PURPOSES: (1) Is surgical resection of the primary tumor associated with improved overall survival in patients with primary malignant bone tumors who have metastatic disease at presentation? (2) What other factors are associated with improved and/or poor overall survival? METHODS: The 2004 to 2016 National Cancer Database (NCDB), a national registry containing data from more than 34 million cancer patients in the United States, was queried using International Classification of Diseases, 3rd Edition, topographical codes to identify patients with primary malignant bone tumors of the extremities (C40.0-C40.3, C40.8, and C40.9) and/or pelvis (C41.4). The NCDB was preferred over other national cancer registries (that is, the Surveillance, Epidemiology, and End Results database) because it includes a specific variable that codes for patients who received additional surgeries at metastatic sites. Patients with malignant bone tumors of the head or skull, trunk, and spinal column were excluded because these patients are not routinely encountered and treated by orthopaedic oncologists. Histologic codes were used to categorize the tumors into the following groups: osteosarcomas, chondrosarcomas, and Ewing sarcomas. Patients whose tumors were classified as Stage 1, 2, or 3 based on American Joint Commission of Cancer guidelines were excluded. Only patients who presented with metastatic disease were included in the final study sample. The study sample was divided into two distinct groups: those who underwent surgical resection of the primary tumor and those who did not receive any operation for the primary tumor. A total of 2288 patients with primary malignant bone tumors (1121 osteosarcomas, 345 chondrosarcomas, and 822 Ewing sarcomas) with metastatic disease at presentation were included, of whom 46% (1053 of 2288) underwent surgical resection of the primary site. Thirty-three percent (348 of 1053) of patients undergoing surgical resection of the primary site also underwent additional resection of metastases. Patients undergoing surgical resection of the primary site typically were younger than 18 years, lived further from a facility, had tumors involving the upper or lower extremity, had a diagnosis of osteosarcoma or chondrosarcoma, and had a greater tumor size and higher tumor grade at presentation. To account for baseline differences within the patient population and to adjust for additional confounding variables, multivariate Cox regression analyses were used to assess whether undergoing surgical resection of the primary tumor was associated with improved overall survival, after controlling for differences in baseline demographics, tumor characteristics (grade, location, histologic type, and tumor size), and treatment patterns (resection of distant or regional metastatic sites, positive or negative surgical margins, and use of radiation therapy or chemotherapy). Additional sensitivity analyses, stratified by histologic type for osteosarcomas, chondrosarcomas, and Ewing sarcomas, were used to assess factors associated with overall survival for each tumor type. RESULTS: After controlling for differences in baseline demographics, tumor characteristics, and treatment patterns, we found that surgical resection of the primary site was associated with reduced overall mortality compared with those who did not have a resection of the primary site (hazard ratio 0.42 [95% confidence interval 0.36 to 0.49]; p < 0.001). Among other factors, in the stratified analysis, radiation therapy was associated with improved overall survival for patients with Ewing sarcoma (HR 0.71 [95% CI 0.57 to 0.88]; p = 0.002) but not for those with osteosarcoma (HR 1.14 [95% CI 0.91 to 1.43]; p = 0.643) or chondrosarcoma (HR 1.0 [95 % CI 0.78 to 1.50]; p = 0.643). Chemotherapy was associated with improved overall survival for those with osteosarcoma (HR 0.50 [95% CI 0.39 to 0.64]; p < 0.001) and those with chondrosarcoma (HR 0.62 [95% CI 0.45 to 0.85]; p = 0.003) but not those with Ewing sarcoma (HR 0.7 [95% CI 0.46 to 1.35]; p = 0.385). CONCLUSIONS: Surgical resection of the primary site was associated with an overall survival advantage in patients with primary malignant bone tumors who presented with metastatic disease. Further research, using more detailed data on metastatic sites (such as, size, location, number, and treatment), chemotherapy regimen and location of radiation (primary or metastatic site) is warranted to better understand which patients will have improved overall survival and/or a benefit in the quality of life from resecting their primary malignant tumor if they present with metastatic disease at diagnosis. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Malik AT, Alexander JH, Mayerson JL, et al. Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation? Clin Orthop Relat Res. 2020. PMID: 32667758. doi:10.1097/CORR.0000000000001361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。